Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT03760653
Other study ID # UEM0002
Secondary ID
Status Withdrawn
Phase N/A
First received
Last updated
Start date October 1, 2018
Est. completion date December 31, 2019

Study information

Verified date May 2022
Source Universidad Europea de Madrid
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Physical exercise along with gut microbiota improvement -because of probiotic intake- can improve the quality of life and immune system in breast cancer survivors. This is achieved because exercise improves the muscle mass in cancer patients (often reduced by treatment and/or inactivity), together with the gut microbiota improvement, this stimulates the inmune system function, improving the quality of life of these patients.


Description:

The aim of this study is to determine the effects of physical exercise together with the supplementation of a probiotic on gut microbiota balance, the gut immune system and quality of life (intended as functional and muscular capacity, physical qualities and emotional state) in breast cancer survivors . A randomized controlled pilot study has been designed in three parallel groups. Breast cancer survivors will be randomly assigned to each of the 3 groups: a) probiotic supplementation + supervised combined physical exercise (PEF), b) probiotic supplementation and habitual sedentary lifestyle (P), and c) control group will follow their usual lifestyle and will receive a placebo (C). The exercise intervention will last 12 weeks. It will include three weekly sessions of programmed physical exercise of ~ 60 min duration (combined training). The exercise program will be individualized and will follow the rules of the world reference institutions for aerobic training. Each session will be held in a qualified fitness center and it will be supervised and individualized for each subject by professional experts .The two supplemented groups will take 3 capsules (Lactobacillus rhamnosus, Lactobacillus paracasei, Lactobacillus acidophilus, Bifidobacterium bifidum) a day (at night before bedtime) for 12 weeks. The variables gut microbiota, fecal levels of immunoglobulin A, cardiorespiratory capacity, anthropometry variables, lifestyle, muscular capacity, quality of life, anxiety, depression and stress levels will be analized at the beginning (baseline dose) and after 12 weeks of intervention.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date December 31, 2019
Est. primary completion date February 1, 2019
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Breast Cancer Survivors - <18 aged. - No chemotherapy treatment or that at least three months have passed after the last chemotherapy treatment before the beginning of the study. - Breast cancer status: I-IV status. - ECOG scale: 0-1. - Normal weight. Exclusion Criteria: - Extreme Diet. - Exercise practice (at least at the doses recommended by WHO) - Presence of heart disease - Uncontrolled blood hypertension: (>160/90 mmHg). - Uncontrolled metabolic disease - Infectious chronic disease - Uncontrolled pain - Pregnancy or breast feeding - Gastrointestinal disease - Alcoholism - Any condition that contraindicates the exercise practice in survivors cancer (fractures risk, severe leukopenia , low platelet count) - Antibiotics intake during the study.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Physical Exercise and probiotic group
The exercise intervention will last 12 weeks. It will include three weekly sessions of programmed physical exercise of ~ 60 min duration (aerobic and strength combined training). The exercise sessions will be individualized and will follow the rules of the world reference institutions for aerobic training. Each session will be held in a authorized fitness center and it will be supervised and individualized for each subject by expert professionals.The probiotic will be taken (3 capsules/day) for 12 weeks. Each probiotic capsule contains Lactobacillus rhamnosus, Lactobacillus paracasei, Lactobacillus acidophilus, Bifidobacterium bifidum.
Dietary Supplement:
Probiotic group
Probiotic supplementation (3 capsules/day) will be taken before bedtime for 12 weeks.Each probiotic capsule contains Lactobacillus rhamnosus, Lactobacillus paracasei, Lactobacillus acidophilus, Bifidobacterium bifidum.
Placebo group
Subjects will take 3 capsules/day of placebo capsules (maltodextrin) for 12 weeks

Locations

Country Name City State
Spain Mar Larrosa Villaviciosa de Odón Madrid

Sponsors (1)

Lead Sponsor Collaborator
Universidad Europea de Madrid

Country where clinical trial is conducted

Spain, 

References & Publications (29)

Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993 Mar 3;85(5):365-76. — View Citation

Battaglini CL, Mills RC, Phillips BL, Lee JT, Story CE, Nascimento MG, Hackney AC. Twenty-five years of research on the effects of exercise training in breast cancer survivors: A systematic review of the literature. World J Clin Oncol. 2014 May 10;5(2):177-90. doi: 10.5306/wjco.v5.i2.177. — View Citation

Benton MJ, Schlairet MC, Gibson DR. Change in quality of life among breast cancer survivors after resistance training: is there an effect of age? J Aging Phys Act. 2014 Apr;22(2):178-85. doi: 10.1123/japa.2012-0227. Epub 2013 Apr 9. — View Citation

Bressa C, Bailén-Andrino M, Pérez-Santiago J, González-Soltero R, Pérez M, Montalvo-Lominchar MG, Maté-Muñoz JL, Domínguez R, Moreno D, Larrosa M. Differences in gut microbiota profile between women with active lifestyle and sedentary women. PLoS One. 2017 Feb 10;12(2):e0171352. doi: 10.1371/journal.pone.0171352. eCollection 2017. — View Citation

Campbell KL, Pusic AL, Zucker DS, McNeely ML, Binkley JM, Cheville AL, Harwood KJ. A prospective model of care for breast cancer rehabilitation: function. Cancer. 2012 Apr 15;118(8 Suppl):2300-11. doi: 10.1002/cncr.27464. Review. — View Citation

Cerdá B, Pérez M, Pérez-Santiago JD, Tornero-Aguilera JF, González-Soltero R, Larrosa M. Gut Microbiota Modification: Another Piece in the Puzzle of the Benefits of Physical Exercise in Health? Front Physiol. 2016 Feb 18;7:51. doi: 10.3389/fphys.2016.00051. eCollection 2016. Review. — View Citation

Cramp F, Byron-Daniel J. Exercise for the management of cancer-related fatigue in adults. Cochrane Database Syst Rev. 2012 Nov 14;11:CD006145. doi: 10.1002/14651858.CD006145.pub3. Review. — View Citation

Dulko D, Pace CM, Dittus KL, Sprague BL, Pollack LA, Hawkins NA, Geller BM. Barriers and facilitators to implementing cancer survivorship care plans. Oncol Nurs Forum. 2013 Nov;40(6):575-80. doi: 10.1188/13.ONF.575-580. — View Citation

Erdman SE, Poutahidis T. Gut bacteria and cancer. Biochim Biophys Acta. 2015 Aug;1856(1):86-90. doi: 10.1016/j.bbcan.2015.05.007. Epub 2015 Jun 4. Review. — View Citation

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015 Mar 1;136(5):E359-86. doi: 10.1002/ijc.29210. Epub 2014 Oct 9. — View Citation

Fong DY, Ho JW, Hui BP, Lee AM, Macfarlane DJ, Leung SS, Cerin E, Chan WY, Leung IP, Lam SH, Taylor AJ, Cheng KK. Physical activity for cancer survivors: meta-analysis of randomised controlled trials. BMJ. 2012 Jan 30;344:e70. doi: 10.1136/bmj.e70. — View Citation

Forsythe LP, Alfano CM, George SM, McTiernan A, Baumgartner KB, Bernstein L, Ballard-Barbash R. Pain in long-term breast cancer survivors: the role of body mass index, physical activity, and sedentary behavior. Breast Cancer Res Treat. 2013 Jan;137(2):617-30. doi: 10.1007/s10549-012-2335-7. Epub 2012 Dec 15. — View Citation

Gnagnarella P, Dragà D, Baggi F, Simoncini MC, Sabbatini A, Mazzocco K, Bassi FD, Pravettoni G, Maisonneuve P. Promoting weight loss through diet and exercise in overweight or obese breast cancer survivors (InForma): study protocol for a randomized controlled trial. Trials. 2016 Jul 28;17:363. doi: 10.1186/s13063-016-1487-x. — View Citation

Goedert JJ, Jones G, Hua X, Xu X, Yu G, Flores R, Falk RT, Gail MH, Shi J, Ravel J, Feigelson HS. Investigation of the association between the fecal microbiota and breast cancer in postmenopausal women: a population-based case-control pilot study. J Natl Cancer Inst. 2015 Jun 1;107(8). pii: djv147. doi: 10.1093/jnci/djv147. Print 2015 Aug. — View Citation

Hallal PC, Victora CG. Reliability and validity of the International Physical Activity Questionnaire (IPAQ). Med Sci Sports Exerc. 2004 Mar;36(3):556. — View Citation

Herrero F, San Juan AF, Fleck SJ, Balmer J, Pérez M, Cañete S, Earnest CP, Foster C, Lucía A. Combined aerobic and resistance training in breast cancer survivors: A randomized, controlled pilot trial. Int J Sports Med. 2006 Jul;27(7):573-80. — View Citation

Lozupone C, Knight R. UniFrac: a new phylogenetic method for comparing microbial communities. Appl Environ Microbiol. 2005 Dec;71(12):8228-35. — View Citation

Minton O, Berger A, Barsevick A, Cramp F, Goedendorp M, Mitchell SA, Stone PC. Cancer-related fatigue and its impact on functioning. Cancer. 2013 Jun 1;119 Suppl 11:2124-30. doi: 10.1002/cncr.28058. Review. — View Citation

Mirandola D, Miccinesi G, Muraca MG, Sgambati E, Monaci M, Marini M. Evidence for adapted physical activity as an effective intervention for upper limb mobility and quality of life in breast cancer survivors. J Phys Act Health. 2014 May;11(4):814-22. doi: 10.1123/jpah.2012-0119. Epub 2013 Apr 5. — View Citation

Mukaida N. Intestinal microbiota: unexpected alliance with tumor therapy. Immunotherapy. 2014;6(3):231-3. doi: 10.2217/imt.13.170. — View Citation

Phillips SM, Dodd KW, Steeves J, McClain J, Alfano CM, McAuley E. Physical activity and sedentary behavior in breast cancer survivors: New insight into activity patterns and potential intervention targets. Gynecol Oncol. 2015 Aug;138(2):398-404. doi: 10.1016/j.ygyno.2015.05.026. Epub 2015 May 28. — View Citation

Rao VP, Poutahidis T, Ge Z, Nambiar PR, Boussahmain C, Wang YY, Horwitz BH, Fox JG, Erdman SE. Innate immune inflammatory response against enteric bacteria Helicobacter hepaticus induces mammary adenocarcinoma in mice. Cancer Res. 2006 Aug 1;66(15):7395-400. — View Citation

Rogers LQ, Courneya KS, Anton PM, Verhulst S, Vicari SK, Robbs RS, McAuley E. Effects of a multicomponent physical activity behavior change intervention on fatigue, anxiety, and depressive symptomatology in breast cancer survivors: randomized trial. Psychooncology. 2017 Nov;26(11):1901-1906. doi: 10.1002/pon.4254. Epub 2016 Sep 6. — View Citation

Saad R, Rizkallah MR, Aziz RK. Gut Pharmacomicrobiomics: the tip of an iceberg of complex interactions between drugs and gut-associated microbes. Gut Pathog. 2012 Nov 30;4(1):16. doi: 10.1186/1757-4749-4-16. — View Citation

Schmitz KH, Courneya KS, Matthews C, Demark-Wahnefried W, Galvão DA, Pinto BM, Irwin ML, Wolin KY, Segal RJ, Lucia A, Schneider CM, von Gruenigen VE, Schwartz AL; American College of Sports Medicine. American College of Sports Medicine roundtable on exercise guidelines for cancer survivors. Med Sci Sports Exerc. 2010 Jul;42(7):1409-26. doi: 10.1249/MSS.0b013e3181e0c112. Erratum in: Med Sci Sports Exerc. 2011 Jan;43(1):195. — View Citation

Travier N, Fonseca-Nunes A, Javierre C, Guillamo E, Arribas L, Peiró I, Buckland G, Moreno F, Urruticoechea A, Oviedo GR, Roca A, Hurtós L, Ortega V, Muñoz M, Garrigós L, Cirauqui B, Del Barco S, Arcusa A, Seguí MA, Borràs JM, Gonzalez CA, Agudo A. Effect of a diet and physical activity intervention on body weight and nutritional patterns in overweight and obese breast cancer survivors. Med Oncol. 2014 Jan;31(1):783. doi: 10.1007/s12032-013-0783-5. Epub 2013 Dec 6. — View Citation

Travier N, Guillamo E, Oviedo GR, Valls J, Buckland G, Fonseca-Nunes A, Alamo JM, Arribas L, Moreno F, Sanz TE, Borras JM, Agudo A, Javierre C. Is Quality of Life Related to Cardiorespiratory Fitness in Overweight and Obese Breast Cancer Survivors? Women Health. 2015;55(5):505-24. doi: 10.1080/03630242.2015.1022817. Epub 2015 Apr 2. — View Citation

van Vliet MJ, Harmsen HJ, de Bont ES, Tissing WJ. The role of intestinal microbiota in the development and severity of chemotherapy-induced mucositis. PLoS Pathog. 2010 May 27;6(5):e1000879. doi: 10.1371/journal.ppat.1000879. Review. — View Citation

Viaud S, Daillère R, Boneca IG, Lepage P, Langella P, Chamaillard M, Pittet MJ, Ghiringhelli F, Trinchieri G, Goldszmid R, Zitvogel L. Gut microbiome and anticancer immune response: really hot Sh*t! Cell Death Differ. 2015 Feb;22(2):199-214. doi: 10.1038/cdd.2014.56. Epub 2014 May 16. Review. — View Citation

* Note: There are 29 references in allClick here to view all references

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Quality of life of breast cancer survivors Breast cancer survivors quality of life will be analyzed with the quality of life questionnaire from The European Organization for Research and Treatment of Cancer EORTC QLQ BR-23 test (a specific module for breast cancer survivors) Quality of life will be analyzed at the beginning (baseline dose) and after 12 weeks of intervention
Secondary Change in Functional capacity Dynamic fitness cardiorespiratory Functional capacity and physical quality will be analyzed at the beginning (baseline dose) and after 12 weeks of exercise intervention
Secondary Change in Body Composition Body Mass Index Functional capacity and physical quality will be analyzed at the beginning (baseline dose) and after 12 weeks of exercise intervention
Secondary Change in Muscular Capacity Pressure manual test will be determined Muscular capacity will be analyzed at the beginning (baseline dose) and after 12 weeks of intervention.
Secondary Change in Dietary habits Food Frequency Questionnaire Lifestyle will be analyzed at the beginning (baseline dose) and after 12 weeks of intervention
Secondary Change in Physical activity level Physical activity questionnaire (IPAQ) will be used Lifestyle will be analyzed at the beginning (baseline dose) and after 12 weeks of intervention
Secondary Change in Anxiety state The State-Trait Anxiety Inventory (STAI) Emotional state will be analyzed at the beginning (baseline dose) and after 12 weeks of intervention
Secondary Change in Depression state Depression inventory (IDER) Emotional state will be analyzed at the beginning (baseline dose) and after 12 weeks of intervention
Secondary Change Stress state Stress coping questionnarie for oncology patients will be used Emotional state will be analyzed at the beginning (baseline dose) and after 12 weeks of intervention
Secondary Change in Gut Microbiota Microbial diversity, bifidobacteria and lactobacillus percentage Gut microbiota will be analyzed at the beginning (baseline dose) and after 12 weeks of intervention)
Secondary Change in Immune system Fecal immunoglobulin A levels Immunoglobulin A levels will be analyzed at the beginning (baseline dose) and after 12 weeks of intervention